- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05947422
CT kvantitativ vurdering av interstitiell lungesykdom
CT kvantitativ vurdering av interstitiell lungesykdom ved bruk av visuelle skår og lungetensitometrimetoder og dens korrelasjon med lungefunksjonstester
Interstitial lung disease (ILD) refers to a broad category of heterogeneous lung diseases with different etiologies and features characterized by inflammation and fibrosis of the lung parenchyma and manifested as exertional dyspnea, interstitial patterns on high resolution computed tomography (HRCT), and abnormal pulmonary function tests (PFTs) The aim of this study is to investigate is there any correlation between changes seen in the lung parenchyma by HRCT and the pulmonary functions of the patients.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study will utilize a cross-sectional prospective study design in a single institution to investigate the correlation between CT chest findings including lung densitometry and pulmonary function test results in patients with ILD.
The study population will consist of consecutive patients diagnosed with ILD recruited from the pulmonary clinic or inpatient service.
High resolution CT chest and pulmonary function tests are routine diagnostic tests used for diagnosis of interstitial lung disease .
both tests are non invasive for the patient and will be acquired for all patients and then their results will be correlated.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ramy M Ahmed, MD
- Telefonnummer: +201153070865
- E-post: ramycolor@aun.edu.eg
Studiesteder
-
-
Asyut Governorate
-
Asyut, Asyut Governorate, Egypt, 71515
- Assiut University Hospital
-
Ta kontakt med:
- Ramy M Ahmed, MD
- Telefonnummer: 01153070865
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population will consist of consecutive patients diagnosed with ILD recruited from the pulmonary clinic or inpatient service. The diagnosis of ILD will be based on American Thoracic Society/European Respiratory Society (ATS/ERS) classification system for ILD.
Beskrivelse
Inclusion Criteria:
- Diagnosis of ILD (based on clinical, radiological, and pulmonary function criteria +/- histopathological criteria).
- Availability of CT chest DICOM images and pulmonary function test results (within a 2-weeks period from each other).
Exclusion Criteria:
- Pregnancy
- Pulmonary edema.
- Primary pulmonary hypertension;
- Chronic obstructive pulmonary disease
- Congestive heart failure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CT visual Warrick score (measured by points)
Tidsramme: baseline
|
Warrick score is calculated as follow : A point value will be given to each abnormality i.e ground-glass appearance (areas of hazy opacity in the lung that do not obscure the underlying bronchial structures) = 1, irregular pleural margins = 2, septal/subpleural lines = 3, honeycombing (usually 3-10 mm in diameter and have thick walls) = 4, and subpleural cysts = 5. In each patient, the "severity of disease" score will be obtained by adding single point values (maximal severity score 15). An "extent of disease" score is obtained by counting the number of bronchopulmonary segments involved for each abnormality as follows ; one to three segments scored as 1, four to nine segments scored as 2, and more than nine segments scored as 3 (maximal extent score 15). The severity and extent of disease will be then calculated as the total Warrick score (range from 0 to 30) |
baseline
|
|
Total lung volume, Volume of lung occupied by low attenuation areas, Volume of lung occupied by high attenuation areas, Volume of normal lung areas and volume of consolidation areas
Tidsramme: baseline
|
Total lung volume , volume of the lung occupied by low attenuation areas (attenuation values from -1024 to -950 HU; representing emphysema), volume of normally attenuated lung (from -949 to -700 HU; corresponds to healthy lung tissue) and volume of the lung occupied by high attenuation areas (between - 699 and - 250 HU) ; it represents the lung parts which are more dense than healthy lung); volume of lung with density from -249 to +40 HU, this group corresponds to areas with further increase in density, including the semi-consolidation and consolidation. |
baseline
|
|
Percentage of the lung occupied by low attenuation areas, percentage of normal lung, percentage of the lung occupied by high attenuation areas and percentage of consolidation areas.
Tidsramme: baseline
|
Percentage of the lung occupied by low attenuation areas (attenuation values from -1024 to -950 HU), percentage of normal lung (from -949 to -700 HU), percentage of the lung occupied by high attenuation areas (between - 699 and - 250 HU) and percentage of consolidation areas (from -249 to +40 HU) in each lung and in each lobe. |
baseline
|
|
Mean lung density of each lung, both lungs and every lobe in Hounsfield unit (HU)
Tidsramme: baseline
|
Mean lung density of each lung , both lungs and each lung lobe (e.g., upper, middle, and lower lobes) will be measured in Hounsfield unit (HU). |
baseline
|
|
Forced vital capacity (FVC)
Tidsramme: baseline
|
Forced vital capacity (FVC) will be measures using spirometer and expressed as percentage. |
baseline
|
|
Forced expiratory volume in 1 second (FEV1)
Tidsramme: baseline
|
Forced expiratory volume in 1 second (FEV1) |
baseline
|
|
FEV1/FVC ratio
Tidsramme: baseline
|
FEV1/FVC ratio will be measures |
baseline
|
|
O2 saturation
Tidsramme: baseline
|
O2 saturation is measured in percentage (SpO2) using pulse oximeter |
baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ramy M Ahmed, MD, Assiut University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ILD-CT
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .